In the article "Adjuvant-dependent immune response to malarial transmission-blocking vaccine candidate antigens" by D. J. Rawlings and D. C. Kaslow (November 1992, 176:1483), the incorrect version of Figure 1 was printed. Below is the correct version of Figure 1.




Figure 1. Immunogenicity of recombinant Pfs40 emulsified in Freund's adjuvant and injected into five congenic mouse strains. Immune sera from congenic mouse strains (B10.BR, B10.D2, B10.A[3], B10.S[7R], B10.S[9R]) immunized with either affinity-purified maltose binding protein (MBP; lanes A) or with rPfs40 partially purified from factor X<sub>2</sub>-cleaved, affinity-purified MBP-rPfs40 fusion protein (lanes B) were assayed by immunoblot analysis of factor X<sub>2</sub>-cleaved, affinity-purified MBP-rPfs40 fusion protein size fractionated by SDS-PAGE under nonreducing conditions and electroblotted to nitrocellulose. Although no inact MBP-rPfs40 fusion protein was detectable by Western blot, the partially purified preparations of rPfs40 contained some MBP, and elicited anti-MBP antibodies in some mouse strains (e.g., B10.A[3R]). The solid line indicates the location of rPfs40 on the nitrocellulose blot, and the arrowhead indicates the location of MBP.